Annual CFO
-$192.61 M
+$111.40 M+36.64%
31 December 2023
Summary:
Nektar Therapeutics annual cash flow from operations is currently -$192.61 million, with the most recent change of +$111.40 million (+36.64%) on 31 December 2023. During the last 3 years, it has risen by +$120.68 million (+38.52%). NKTR annual CFO is now -126.82% below its all-time high of $718.21 million, reached on 31 December 2018.NKTR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$43.93 M
-$6.23 M-16.52%
30 September 2024
Summary:
Nektar Therapeutics quarterly cash flow from operations is currently -$43.93 million, with the most recent change of -$6.23 million (-16.52%) on 30 September 2024. Over the past year, it has dropped by -$1.81 million (-4.30%). NKTR quarterly CFO is now -104.58% below its all-time high of $959.64 million, reached on 30 June 2018.NKTR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$176.57 M
-$1.81 M-1.04%
30 September 2024
Summary:
Nektar Therapeutics TTM cash flow from operations is currently -$176.57 million, with the most recent change of -$1.81 million (-1.04%) on 30 September 2024. Over the past year, it has increased by +$26.69 million (+13.13%). NKTR TTM CFO is now -119.20% below its all-time high of $919.85 million, reached on 30 June 2018.NKTR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +36.6% | -4.3% | +13.1% |
| 3 y3 years | +38.5% | +56.6% | +50.9% |
| 5 y5 years | -126.8% | +36.0% | +45.0% |
NKTR Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +53.3% | -16.5% | +71.0% | -1.0% | +58.4% |
| 5 y | 5 years | -126.8% | +53.3% | -16.5% | +71.0% | -1.0% | +58.4% |
| alltime | all time | -126.8% | +53.3% | -104.6% | +71.0% | -119.2% | +58.4% |
Nektar Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$43.93 M(+16.5%) | -$176.57 M(+1.0%) |
| June 2024 | - | -$37.70 M(-21.3%) | -$174.76 M(-7.3%) |
| Mar 2024 | - | -$47.89 M(+1.8%) | -$188.58 M(-2.1%) |
| Dec 2023 | -$192.61 M(-36.6%) | -$47.05 M(+11.7%) | -$192.61 M(-5.2%) |
| Sept 2023 | - | -$42.12 M(-18.2%) | -$203.26 M(-16.7%) |
| June 2023 | - | -$51.52 M(-0.8%) | -$244.03 M(-8.8%) |
| Mar 2023 | - | -$51.91 M(-10.0%) | -$267.50 M(-12.0%) |
| Dec 2022 | -$304.01 M(-26.3%) | -$57.70 M(-30.4%) | -$304.01 M(-23.6%) |
| Sept 2022 | - | -$82.89 M(+10.5%) | -$397.84 M(-4.4%) |
| June 2022 | - | -$74.99 M(-15.2%) | -$416.09 M(-1.9%) |
| Mar 2022 | - | -$88.42 M(-41.6%) | -$424.00 M(+2.7%) |
| Dec 2021 | -$412.66 M(+31.7%) | -$151.54 M(+49.8%) | -$412.66 M(+14.7%) |
| Sept 2021 | - | -$101.14 M(+22.0%) | -$359.76 M(+15.6%) |
| June 2021 | - | -$82.90 M(+7.5%) | -$311.30 M(-0.3%) |
| Mar 2021 | - | -$77.08 M(-21.8%) | -$312.30 M(-0.3%) |
| Dec 2020 | -$313.29 M(-4.7%) | -$98.63 M(+87.3%) | -$313.29 M(-7.8%) |
| Sept 2020 | - | -$52.67 M(-37.2%) | -$339.88 M(-4.5%) |
| June 2020 | - | -$83.90 M(+7.5%) | -$355.84 M(+9.2%) |
| Mar 2020 | - | -$78.08 M(-37.7%) | -$325.86 M(-0.9%) |
| Dec 2019 | -$328.68 M(-145.8%) | -$125.22 M(+82.4%) | -$328.68 M(+2.4%) |
| Sept 2019 | - | -$68.64 M(+27.3%) | -$321.01 M(-0.9%) |
| June 2019 | - | -$53.92 M(-33.3%) | -$323.78 M(-146.9%) |
| Mar 2019 | - | -$80.89 M(-31.2%) | $689.78 M(-4.0%) |
| Dec 2018 | $718.21 M(-993.1%) | -$117.55 M(+64.6%) | $718.21 M(-4.9%) |
| Sept 2018 | - | -$71.41 M(-107.4%) | $755.36 M(-17.9%) |
| June 2018 | - | $959.64 M(-1929.1%) | $919.85 M(-1035.6%) |
| Mar 2018 | - | -$52.47 M(-34.7%) | -$98.31 M(+22.3%) |
| Dec 2017 | -$80.41 M(-31.3%) | -$80.40 M(-186.4%) | -$80.41 M(+53.4%) |
| Sept 2017 | - | $93.08 M(-259.0%) | -$52.42 M(-69.7%) |
| June 2017 | - | -$58.52 M(+69.3%) | -$172.86 M(+35.1%) |
| Mar 2017 | - | -$34.57 M(-34.0%) | -$127.94 M(+9.3%) |
| Dec 2016 | -$117.02 M(+60.1%) | -$52.41 M(+91.6%) | -$117.02 M(-16.2%) |
| Sept 2016 | - | -$27.36 M(+101.1%) | -$139.72 M(+10.5%) |
| June 2016 | - | -$13.60 M(-42.5%) | -$126.39 M(-21.0%) |
| Mar 2016 | - | -$23.65 M(-68.5%) | -$160.04 M(+119.0%) |
| Dec 2015 | -$73.08 M(-48.5%) | -$75.11 M(+435.3%) | -$73.08 M(+223.4%) |
| Sept 2015 | - | -$14.03 M(-70.3%) | -$22.60 M(-58.6%) |
| June 2015 | - | -$47.26 M(-174.6%) | -$54.57 M(+232.7%) |
| Mar 2015 | - | $63.31 M(-357.1%) | -$16.40 M(-88.4%) |
| Dec 2014 | -$142.01 M(+268.6%) | -$24.63 M(-46.5%) | -$142.01 M(+122.8%) |
| Sept 2014 | - | -$46.00 M(+406.4%) | -$63.75 M(+70.2%) |
| June 2014 | - | -$9.09 M(-85.4%) | -$37.45 M(-40.3%) |
| Mar 2014 | - | -$62.29 M(-216.1%) | -$62.71 M(+62.8%) |
| Dec 2013 | -$38.53 M(-70.3%) | $53.63 M(-372.1%) | -$38.53 M(-72.4%) |
| Sept 2013 | - | -$19.71 M(-42.6%) | -$139.53 M(-5.1%) |
| June 2013 | - | -$34.34 M(-9.9%) | -$147.00 M(+10.3%) |
| Mar 2013 | - | -$38.11 M(-19.6%) | -$133.25 M(+2.7%) |
| Dec 2012 | -$129.76 M(+14.1%) | -$47.38 M(+74.4%) | -$129.76 M(+4.1%) |
| Sept 2012 | - | -$27.17 M(+32.0%) | -$124.59 M(+4.4%) |
| June 2012 | - | -$20.59 M(-40.5%) | -$119.29 M(-10.6%) |
| Mar 2012 | - | -$34.62 M(-18.0%) | -$133.49 M(+17.4%) |
| Dec 2011 | -$113.74 M(+103.6%) | -$42.21 M(+93.0%) | -$113.74 M(+122.5%) |
| Sept 2011 | - | -$21.87 M(-37.1%) | -$51.12 M(-0.6%) |
| June 2011 | - | -$34.79 M(+133.9%) | -$51.41 M(+40.6%) |
| Mar 2011 | - | -$14.87 M(-172.9%) | -$36.58 M(-34.5%) |
| Dec 2010 | -$55.87 M(-240.6%) | $20.41 M(-192.1%) | -$55.87 M(-203.6%) |
| Sept 2010 | - | -$22.16 M(+11.1%) | $53.91 M(-4.9%) |
| June 2010 | - | -$19.95 M(-41.6%) | $56.70 M(+18.2%) |
| Mar 2010 | - | -$34.16 M(-126.2%) | $47.97 M(+20.7%) |
| Dec 2009 | $39.74 M | $130.19 M(-771.9%) | $39.74 M(-132.8%) |
| Sept 2009 | - | -$19.38 M(-32.4%) | -$121.17 M(+0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$28.68 M(-32.3%) | -$120.43 M(-2.2%) |
| Mar 2009 | - | -$42.39 M(+38.0%) | -$123.20 M(-15.5%) |
| Dec 2008 | -$145.78 M(-199.6%) | -$30.72 M(+64.8%) | -$145.78 M(+1648.4%) |
| Sept 2008 | - | -$18.64 M(-40.7%) | -$8.34 M(-112.9%) |
| June 2008 | - | -$31.45 M(-51.6%) | $64.56 M(-41.5%) |
| Mar 2008 | - | -$64.97 M(-160.9%) | $110.33 M(-24.6%) |
| Dec 2007 | $146.30 M(-257.8%) | $106.73 M(+96.7%) | $146.30 M(+975.1%) |
| Sept 2007 | - | $54.26 M(+279.2%) | $13.61 M(-137.9%) |
| June 2007 | - | $14.31 M(-149.3%) | -$35.94 M(-56.7%) |
| Mar 2007 | - | -$29.00 M(+11.7%) | -$82.99 M(-10.5%) |
| Dec 2006 | -$92.72 M(+18.9%) | -$25.97 M(-650.8%) | -$92.72 M(+11.9%) |
| Sept 2006 | - | $4.71 M(-114.4%) | -$82.87 M(-26.6%) |
| June 2006 | - | -$32.74 M(-15.4%) | -$112.95 M(+10.4%) |
| Mar 2006 | - | -$38.72 M(+140.1%) | -$102.35 M(+31.2%) |
| Dec 2005 | -$78.00 M(-0.2%) | -$16.13 M(-36.4%) | -$78.00 M(+12.6%) |
| Sept 2005 | - | -$25.36 M(+14.5%) | -$69.28 M(+22.8%) |
| June 2005 | - | -$22.15 M(+54.2%) | -$56.42 M(-15.9%) |
| Mar 2005 | - | -$14.36 M(+94.0%) | -$67.10 M(-14.1%) |
| Dec 2004 | -$78.14 M(+2.5%) | -$7.41 M(-40.8%) | -$78.14 M(-6.2%) |
| Sept 2004 | - | -$12.50 M(-61.9%) | -$83.35 M(+1.3%) |
| June 2004 | - | -$32.83 M(+29.2%) | -$82.32 M(+33.4%) |
| Mar 2004 | - | -$25.41 M(+101.5%) | -$61.70 M(-19.0%) |
| Dec 2003 | -$76.20 M(+1.6%) | -$12.61 M(+9.9%) | -$76.20 M(-0.1%) |
| Sept 2003 | - | -$11.47 M(-6.1%) | -$76.29 M(-13.3%) |
| June 2003 | - | -$12.21 M(-69.4%) | -$87.94 M(-8.3%) |
| Mar 2003 | - | -$39.91 M(+214.3%) | -$95.85 M(+27.8%) |
| Dec 2002 | -$74.97 M(+47.7%) | -$12.70 M(-45.1%) | -$74.97 M(+7.0%) |
| Sept 2002 | - | -$23.13 M(+14.9%) | -$70.04 M(-10.1%) |
| June 2002 | - | -$20.12 M(+5.7%) | -$77.88 M(+36.7%) |
| Mar 2002 | - | -$19.03 M(+145.3%) | -$56.97 M(+12.2%) |
| Dec 2001 | -$50.77 M(+42.1%) | -$7.76 M(-75.0%) | -$50.77 M(+10.1%) |
| Sept 2001 | - | -$30.97 M(-4020.8%) | -$46.10 M(+33.7%) |
| June 2001 | - | $790.00 K(-106.2%) | -$34.47 M(-26.2%) |
| Mar 2001 | - | -$12.83 M(+315.8%) | -$46.68 M(+30.6%) |
| Dec 2000 | -$35.74 M(+133.1%) | -$3.09 M(-84.0%) | -$35.74 M(+9.7%) |
| Sept 2000 | - | -$19.34 M(+69.4%) | -$32.59 M(+137.1%) |
| June 2000 | - | -$11.42 M(+504.3%) | -$13.75 M(+0.8%) |
| Mar 2000 | - | -$1.89 M(-2963.6%) | -$13.64 M(-11.1%) |
| Dec 1999 | -$15.33 M(-20.2%) | $66.00 K(-113.2%) | -$15.33 M(-14.0%) |
| Sept 1999 | - | -$500.00 K(-95.6%) | -$17.82 M(-23.5%) |
| June 1999 | - | -$11.31 M(+215.5%) | -$23.31 M(+59.2%) |
| Mar 1999 | - | -$3.59 M(+48.0%) | -$14.64 M(-23.8%) |
| Dec 1998 | -$19.22 M(-486.1%) | -$2.42 M(-59.5%) | -$19.22 M(+96.0%) |
| Sept 1998 | - | -$5.99 M(+125.8%) | -$9.81 M(+139.0%) |
| June 1998 | - | -$2.65 M(-67.5%) | -$4.10 M(-18.8%) |
| Mar 1998 | - | -$8.16 M(-216.7%) | -$5.05 M(-201.5%) |
| Dec 1997 | $4.98 M(-185.8%) | $6.99 M(-2580.1%) | $4.98 M(-546.5%) |
| Sept 1997 | - | -$282.00 K(-92.2%) | -$1.11 M(-67.5%) |
| June 1997 | - | -$3.60 M(-292.8%) | -$3.43 M(+268.3%) |
| Mar 1997 | - | $1.87 M(+107.6%) | -$932.00 K(-83.9%) |
| Dec 1996 | -$5.80 M(+9.4%) | $900.00 K(-134.6%) | -$5.80 M(-29.3%) |
| Sept 1996 | - | -$2.60 M(+136.4%) | -$8.20 M(+18.8%) |
| June 1996 | - | -$1.10 M(-63.3%) | -$6.90 M(-6.8%) |
| Mar 1996 | - | -$3.00 M(+100.0%) | -$7.40 M(+39.6%) |
| Dec 1995 | -$5.30 M(+32.5%) | -$1.50 M(+15.4%) | -$5.30 M(-19.7%) |
| Sept 1995 | - | -$1.30 M(-18.8%) | -$6.60 M(+20.0%) |
| June 1995 | - | -$1.60 M(+77.8%) | -$5.50 M(+10.0%) |
| Mar 1995 | - | -$900.00 K(-67.9%) | -$5.00 M(+25.0%) |
| Dec 1994 | -$4.00 M | -$2.80 M(+1300.0%) | -$4.00 M(+233.3%) |
| Sept 1994 | - | -$200.00 K(-81.8%) | -$1.20 M(+20.0%) |
| June 1994 | - | -$1.10 M(-1200.0%) | -$1.00 M(-1100.0%) |
| Mar 1994 | - | $100.00 K | $100.00 K |
FAQ
- What is Nektar Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Nektar Therapeutics?
- What is Nektar Therapeutics annual CFO year-on-year change?
- What is Nektar Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly CFO year-on-year change?
- What is Nektar Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Nektar Therapeutics?
- What is Nektar Therapeutics TTM CFO year-on-year change?
What is Nektar Therapeutics annual cash flow from operations?
The current annual CFO of NKTR is -$192.61 M
What is the all time high annual CFO for Nektar Therapeutics?
Nektar Therapeutics all-time high annual cash flow from operations is $718.21 M
What is Nektar Therapeutics annual CFO year-on-year change?
Over the past year, NKTR annual cash flow from operations has changed by +$111.40 M (+36.64%)
What is Nektar Therapeutics quarterly cash flow from operations?
The current quarterly CFO of NKTR is -$43.93 M
What is the all time high quarterly CFO for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly cash flow from operations is $959.64 M
What is Nektar Therapeutics quarterly CFO year-on-year change?
Over the past year, NKTR quarterly cash flow from operations has changed by -$1.81 M (-4.30%)
What is Nektar Therapeutics TTM cash flow from operations?
The current TTM CFO of NKTR is -$176.57 M
What is the all time high TTM CFO for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM cash flow from operations is $919.85 M
What is Nektar Therapeutics TTM CFO year-on-year change?
Over the past year, NKTR TTM cash flow from operations has changed by +$26.69 M (+13.13%)